745 related articles for article (PubMed ID: 33357641)
1. Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study.
Jain AR; Aggarwal RK; Rao NS; Billa G; Kumar S
Indian Heart J; 2020; 72(6):535-540. PubMed ID: 33357641
[TBL] [Abstract][Full Text] [Related]
2. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
3. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
Rohde LE; Claggett BL; Wolsk E; Packer M; Zile M; Swedberg K; Rouleau J; Pfeffer MA; Desai AS; Lund LH; Kober L; Anand I; Merkely B; Senni M; Shi V; Rizkala A; Lefkowitz M; McMurray JJV; Solomon SD
Circ Heart Fail; 2021 Mar; 14(3):e008052. PubMed ID: 33706551
[TBL] [Abstract][Full Text] [Related]
4. Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex.
Mitchell GF; Solomon SD; Shah AM; Claggett BL; Fang JC; Izzo J; Abbas CA; Desai AS;
Circ Heart Fail; 2021 Mar; 14(3):e007891. PubMed ID: 33663237
[TBL] [Abstract][Full Text] [Related]
5. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
[TBL] [Abstract][Full Text] [Related]
6. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF.
Ehteshami-Afshar S; Mooney L; Dewan P; Desai AS; Lang NN; Lefkowitz MP; Petrie MC; Rizkala AR; Rouleau JL; Solomon SD; Swedberg K; Shi VC; Zile MR; Packer M; McMurray JJV; Jhund PS; Hawkins NM
J Am Heart Assoc; 2021 Feb; 10(4):e019238. PubMed ID: 33522249
[TBL] [Abstract][Full Text] [Related]
7. Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan.
Curtain JP; Adamson C; Docherty KF; Jhund PS; Desai AS; Lefkowitz MP; Rizkala AR; Rouleau JL; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJV
JACC Heart Fail; 2023 Jul; 11(7):749-759. PubMed ID: 37407154
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction.
Tan NY; Sangaralingham LR; Sangaralingham SJ; Yao X; Shah ND; Dunlay SM
JACC Heart Fail; 2020 Jan; 8(1):43-54. PubMed ID: 31838035
[TBL] [Abstract][Full Text] [Related]
9. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.
Chandra A; Lewis EF; Claggett BL; Desai AS; Packer M; Zile MR; Swedberg K; Rouleau JL; Shi VC; Lefkowitz MP; Katova T; McMurray JJV; Solomon SD
JAMA Cardiol; 2018 Jun; 3(6):498-505. PubMed ID: 29617523
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial.
Berg DD; Samsky MD; Velazquez EJ; Duffy CI; Gurmu Y; Braunwald E; Morrow DA; DeVore AD
Circ Heart Fail; 2021 Feb; 14(2):e007034. PubMed ID: 33530704
[TBL] [Abstract][Full Text] [Related]
11. Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure.
Morrow DA; Velazquez EJ; Desai AS; DeVore AD; Lepage S; Park JG; Sharma K; Solomon SD; Starling RC; Ward JH; Williamson KM; Zieroth S; Hernandez AF; Mentz RJ; Braunwald E
J Am Coll Cardiol; 2024 Mar; 83(12):1123-1132. PubMed ID: 38508844
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction - Results From the PARALLEL-HF Study.
Tsutsui H; Momomura SI; Saito Y; Ito H; Yamamoto K; Sakata Y; Desai AS; Ohishi T; Iimori T; Kitamura T; Guo W;
Circ J; 2021 Apr; 85(5):584-594. PubMed ID: 33731544
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
Gaziano TA; Fonarow GC; Claggett B; Chan WW; Deschaseaux-Voinet C; Turner SJ; Rouleau JL; Zile MR; McMurray JJ; Solomon SD
JAMA Cardiol; 2016 Sep; 1(6):666-72. PubMed ID: 27438344
[TBL] [Abstract][Full Text] [Related]
14. The AWAKE-HF Study: Sacubitril/Valsartan Impact on Daily Physical Activity and Sleep in Heart Failure.
Khandwalla RM; Grant D; Birkeland K; Heywood JT; Fombu E; Owens RL; Steinhubl SR;
Am J Cardiovasc Drugs; 2021 Mar; 21(2):241-254. PubMed ID: 32978755
[TBL] [Abstract][Full Text] [Related]
15. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
[TBL] [Abstract][Full Text] [Related]
16. Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF.
Zile MR; O'Meara E; Claggett B; Prescott MF; Solomon SD; Swedberg K; Packer M; McMurray JJV; Shi V; Lefkowitz M; Rouleau J
J Am Coll Cardiol; 2019 Feb; 73(7):795-806. PubMed ID: 30784673
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
[TBL] [Abstract][Full Text] [Related]
18. A randomized clinical trial on the short-term effects of 12-week sacubitril/valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results from the ACTIVITY-HF study.
Halle M; Schöbel C; Winzer EB; Bernhardt P; Mueller S; Sieder C; Lecker LSM
Eur J Heart Fail; 2021 Dec; 23(12):2073-2082. PubMed ID: 34591356
[TBL] [Abstract][Full Text] [Related]
19. Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF.
Balmforth C; Simpson J; Shen L; Jhund PS; Lefkowitz M; Rizkala AR; Rouleau JL; Shi V; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
JACC Heart Fail; 2019 Jun; 7(6):457-465. PubMed ID: 31078482
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial.
Berg DD; Braunwald E; DeVore AD; Lala A; Pinney SP; Duffy CI; Gurmu Y; Velazquez EJ; Morrow DA
JACC Heart Fail; 2020 Oct; 8(10):834-843. PubMed ID: 32800511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
